A carregar...
The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. However, the disease will inevitably progress over time due to acquired resistance. Longitudinal...
Na minha lista:
| Publicado no: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6873100/ https://ncbi.nlm.nih.gov/pubmed/31762748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503417 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|